Moderna Stock Is Just The Start: Why AI-Focused Money Might Flow Into Biotech

Moderna (MRNA) stock surged 177% to a three-year high on Wednesday after the Cambridge, Mass.-based company reported positive results in a cancer vaccine trial showing longer relapse times, and Investor's Business Daily suggests this could signal AI-focused investment shifting from data-center plays to biotech applications of generative AI.

Moderna stock's recent surge might herald a shift in AI-focused dollars away from memory and data-center plays … and toward applications of generative AI tech. On Wednesday, Cambridge, Mass.-based Moderna MRNA soared 177% to hit a three-year high after announcing positive results in testing a vaccine for certain types of cancer. The tests showed a lengthening in relapses among patients… Moderna Stock Is Just The Start: Why AI-Focused Money Might Flow Into Biotech Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8